Profile data is unavailable for this security.
About the company
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
- Revenue in USD (TTM)42.51k
- Net income in USD-43.46m
- Incorporated1987
- Employees--
- LocationImmutep LtdPlaza Building, L 12 95 Pitt StSYDNEY 2000AustraliaAUS
- Phone+61 28315-7003
- Fax+61 28569-1880
- Websitehttps://www.immutep.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Forte Biosciences Inc | 0.00 | -51.74m | 369.29m | 16.00 | -- | 4.39 | -- | -- | -4.49 | -4.49 | 0.00 | 6.71 | 0.00 | -- | -- | 0.00 | -89.96 | -64.69 | -110.72 | -71.52 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.71 | -- | -38.72 | -- |
| Climb Bio Inc | 0.00 | -50.75m | 375.01m | 17.00 | -- | 2.12 | -- | -- | -0.7507 | -0.7507 | 0.00 | 2.60 | 0.00 | -- | -- | 0.00 | -25.09 | -39.53 | -25.62 | -41.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -110.42 | -- | -- | -- |
| PepGen Inc | 0.00 | -93.56m | 378.80m | 81.00 | -- | 2.32 | -- | -- | -2.84 | -2.84 | 0.00 | 2.37 | 0.00 | -- | -- | 0.00 | -51.93 | -45.06 | -56.56 | -49.76 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.44 | -- | 76.52 | -- |
| Allogene Therapeutics Inc | 0.00 | -212.02m | 379.79m | 226.00 | -- | 1.20 | -- | -- | -0.981 | -0.981 | 0.00 | 1.41 | 0.00 | -- | -- | 0.00 | -41.21 | -31.11 | -43.96 | -33.14 | -- | -- | -- | -1,187.06 | -- | -- | 0.00 | -- | -76.84 | -- | 21.29 | -- | -57.62 | -- |
| Monopar Therapeutics Inc | 0.00 | -19.44m | 381.38m | 16.00 | -- | 2.69 | -- | -- | -3.44 | -3.44 | 0.00 | 21.25 | 0.00 | -- | -- | 0.00 | -25.88 | -52.66 | -26.53 | -59.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -85.50 | -- | -- | -- |
| Northwest Biotherapeutics Inc | 937.00k | -91.22m | 382.93m | 25.00 | -- | -- | -- | 408.68 | -0.0655 | -0.0655 | 0.0007 | -0.0627 | 0.0313 | -- | -- | 37,480.00 | -299.59 | -398.92 | -- | -- | -- | -- | -9,580.90 | -8,255.92 | -- | -6.69 | -- | -- | -28.47 | -10.53 | -32.34 | -- | 23.01 | -- |
| Greenwich Lifesciences Inc | 0.00 | -19.48m | 387.79m | 4.00 | -- | 176.71 | -- | -- | -1.46 | -1.46 | 0.00 | 0.1584 | 0.00 | -- | -- | 0.00 | -404.39 | -49.65 | -543.43 | -51.94 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.57 | -- | -- | -- |
| Bicycle Therapeutics PLC (ADR) | 28.34m | -250.66m | 390.54m | 305.00 | -- | 0.6309 | -- | 13.78 | -3.62 | -3.62 | 0.4094 | 8.92 | 0.0322 | -- | 0.4525 | 92,914.76 | -28.47 | -26.61 | -30.66 | -29.60 | -- | -- | -884.51 | -587.28 | -- | -- | 0.0015 | -- | 30.76 | 20.65 | 6.44 | -- | -4.50 | -- |
| Immutep Ltd - ADR | 42.51k | -43.46m | 390.94m | -- | -- | -- | -- | 9,195.43 | -0.2984 | -0.2984 | 0.0003 | -- | 0.0003 | -- | 0.0991 | -- | -34.27 | -32.47 | -36.64 | -34.65 | -- | -- | -102,219.90 | -21,963.05 | -- | -- | 0.0112 | -- | -49.76 | -62.18 | -43.82 | -- | 69.56 | -- |
| Tectonic Therapeutic Inc | 0.00 | -67.30m | 393.98m | 51.00 | -- | 1.47 | -- | -- | -3.85 | -3.85 | 0.00 | 14.30 | 0.00 | -- | -- | 0.00 | -30.20 | -- | -32.12 | -- | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -35.40 | -- | -- | -- |
| NovaBridge Biosciences | 0.00 | -26.33m | 394.30m | 32.00 | -- | 1.52 | -- | -- | -0.3045 | -0.2827 | 0.00 | 2.25 | 0.00 | -- | -- | 0.00 | -10.32 | -26.21 | -10.92 | -30.19 | -- | -- | -- | -389.26 | -- | -- | 0.00 | -- | -100.00 | -- | 39.56 | -- | -51.41 | -- |
| Aclaris Therapeutics Inc | 15.74m | -141.68m | 395.46m | 64.00 | -- | 3.29 | -- | 25.12 | -1.38 | -1.38 | 0.136 | 1.11 | 0.088 | -- | 6.27 | 245,968.80 | -79.17 | -48.16 | -90.39 | -55.11 | 3.98 | 40.68 | -900.01 | -483.49 | -- | -- | 0.00 | -- | -40.09 | 34.67 | -49.26 | -- | 86.02 | -- |
| Benitec Biopharma Inc | 0.00 | -41.82m | 396.19m | 19.00 | -- | 3.28 | -- | -- | -1.18 | -1.18 | 0.00 | 3.57 | 0.00 | -- | -- | 0.00 | -50.76 | -79.73 | -52.87 | -88.81 | -- | 88.41 | -- | -53,777.78 | -- | -- | 0.00 | -- | -- | -- | -69.50 | -- | -28.30 | -- |
| Absci Corp | 2.82m | -114.60m | 396.98m | 156.00 | -- | 1.88 | -- | 141.02 | -0.903 | -0.903 | 0.022 | 1.40 | 0.0117 | -- | 2.25 | 18,044.87 | -47.73 | -37.10 | -54.08 | -41.33 | -- | -- | -4,071.19 | -1,697.47 | -- | -410.97 | 0.0065 | -- | -20.71 | 17.09 | 6.75 | -- | -18.12 | -- |
| Niagen Bioscience Inc | 124.71m | 20.43m | 408.61m | 104.00 | 21.07 | 5.77 | 19.27 | 3.28 | 0.243 | 0.243 | 1.48 | 0.8875 | 1.61 | 3.07 | 18.34 | 1,199,125.00 | 26.42 | -23.12 | 35.76 | -35.20 | 63.89 | 60.73 | 16.38 | -15.71 | 3.29 | -- | 0.00003 | -- | 19.18 | 16.56 | 273.15 | -- | -26.37 | -- |
Data as of Feb 11 2026. Currency figures normalised to Immutep Ltd's reporting currency: US Dollar USD
1.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Pengana Capital Ltd.as of 31 Oct 2025 | 970.61k | 0.66% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 580.44k | 0.39% |
| Meridian Wealth Management LLCas of 31 Dec 2025 | 454.40k | 0.31% |
| Sender Co. & Partners, Inc.as of 30 Sep 2025 | 215.86k | 0.15% |
| Morgan Stanley & Co. LLCas of 30 Sep 2025 | 160.47k | 0.11% |
| Susquehanna Financial Group LLLPas of 30 Sep 2025 | 95.25k | 0.07% |
| Verition Fund Management LLCas of 30 Sep 2025 | 75.00k | 0.05% |
| UBS Securities LLCas of 31 Dec 2025 | 70.42k | 0.05% |
| Jane Street Capital LLCas of 30 Sep 2025 | 55.46k | 0.04% |
| Steward Partners Investment Advisory LLCas of 30 Sep 2025 | 55.00k | 0.04% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
